Immutep announces positive efficacy and safety results from the TACTI-003 Phase IIb trial evaluating eftilagimod alpha in combination with MSD’s (MRK) anti-PD-1 therapy KEYTRUDA as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients, 1L HNSCC. Efti in combination with pembrolizumab led to a 32.8% ORR in evaluable patients with CPS greater than or equal to1 compared to 26.7% for pembrolizumab in evaluable patients with CPS greater than or equal to1, according to RECIST 1.1. Imbalances of prognostic markers towards the pembrolizumab alone arm included HPV status, smoking status, and primary tumour location. Durability of response was achieved with the addition of efti with a median DOR of 17.5 months in the E+P arm. Efti in combination with pembrolizumab continues to have a favourable safety profile with no new safety signals observed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
- Immutep: Quarterly Rebalance of S&P/ASX Indices
- Immutep Reports Increased Loss Despite Higher Income
- Immutep Launches Groundbreaking Autoimmune Therapy Trial
- Immutep announces first participant dosed in Phase I study of IMP761